Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses

Overview

Journal Eur Urol Open Sci

Date 2024 Sep 11

PMID 39257620

Authors

Richard S Matulewicz

Fady Baky

Andrea Knezevic

Joel Sheinfeld

Brandon M Williams

Rachel E Kantor

Nicole Liso

Jahwa Hossain

Maria Bromberg

Alisa Valentino

Rachel So

Samuel A Funt

Fei Ye

Darren R Feldman

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNAs (miRNAs) show promise as blood-based tumor markers for germ cell tumors (GCTs), with miRNA-371-3p being the most studied. The marginal benefit of including other candidate miRNAs to aid with the management of testicular GCTs remains unclear.

Objective: To assess the performance of our combined miRNA assay (371a-3p and 372-3p) in patients with clinically localized testicular masses.

Design Setting And Participants: This was a retrospective review of patients prospectively enrolled in an ongoing protocol collecting serum miR-371a-3p and miR-372-3p levels (together, Memorial Sloan Kettering Cancer Center [MSK] miRNA assay [MMA]) in patients with a suspected or diagnosed testicular GCT.

Outcome Measurements And Statistical Analysis: The coprimary outcomes of interest were sensitivity and specificity of miR-371a-3p and 372-3p, individually and together, to detect nonteratomatous GCTs in the orchiectomy specimen. Secondary outcomes included additional assay diagnostic parameters, the relationship of patient and disease factors with variations in miRNA levels, and temporal patterns of miRNA normalization after orchiectomy.

Results And Limitations: Sixty-two patients were included, 52 had a viable GCT at orchiectomy, and ten had no cancer or a non-GCT. Forty-six patients with a GCT had positive preorchiectomy MMA (sensitivity 88.5% [95% confidence interval {CI}: 79.8, 97.2]), and one patient had positive preorchiectomy MMA but no GCT (specificity 90.0% [95% CI: 71.4, 100]). The diagnostic performance of miR-371a-3-p and miR-372-3p was similar. The time for miRNA to decrease to undetectable levels varied, with some patients having positive levels up to 3 wk after orchiectomy.

Conclusions: The biomarkers miR-371a-3p and miR-372-3p demonstrated high sensitivity and specificity for localized testicular GCTs, but causes of variation in relative miRNA levels and time to normalization for individual patients remain unclear.

Patient Summary: We studied the ability of the blood-based biomarkers miR-371a-3p and miR-372-3p to detect testicular cancer (germ cell tumors) in patients with small testicular masses. We found that together and individually these were sensitive and specific for testicular cancer.

Citing Articles

Non-Invasive miRNA Profiling for Differential Diagnosis and Prognostic Stratification of Testicular Germ Cell Tumors.

Vlachostergios P, Evmorfopoulos K, Zachos I, Dimitropoulos K, Thodou E, Samara M Genes (Basel). 2025; 15(12.

PMID: 39766916 PMC: 11728082. DOI: 10.3390/genes15121649.

References

Ling H, Krassnig L, Bullock M, Pichler M . MicroRNAs in Testicular Cancer Diagnosis and Prognosis. Urol Clin North Am. 2015; 43(1):127-34. DOI: 10.1016/j.ucl.2015.08.013. View

Dieckmann K, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U . Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 2019; 37(16):1412-1423. PMC: 6544462. DOI: 10.1200/JCO.18.01480. View

Myklebust M, Thor A, Rosenlund B, Gjengsto P, Karlsdottir A, Brydoy M . Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. Sci Rep. 2021; 11(1):15582. PMC: 8329070. DOI: 10.1038/s41598-021-94812-2. View

Germa J, Arcusa A, Casamitjana R . False elevations of human chorionic gonadotropin associated to iatrogenic hypogonadism in gonadal germ cell tumors. Cancer. 1987; 60(10):2489-93. DOI: 10.1002/1097-0142(19871115)60:10<2489::aid-cncr2820601024>3.0.co;2-b. View

Javadpour N, Soares T . False-positive and false-negative alpha-feto protein and human chorionic gonadotropin assays in testicular cancer: a double blind study. Cancer. 1981; 48(10):2279-81. DOI: 10.1002/1097-0142(19811115)48:10<2279::aid-cncr2820481025>3.0.co;2-e. View

Lange P, Winfield H . Biological markers in urologic cancer. Cancer. 1987; 60(3 Suppl):464-72. DOI: 10.1002/1097-0142(19870801)60:3+<464::aid-cncr2820601506>3.0.co;2-c. View

Ehrlich Y, Beck S, Foster R, Bihrle R, Einhorn L . Serum tumor markers in testicular cancer. Urol Oncol. 2010; 31(1):17-23. DOI: 10.1016/j.urolonc.2010.04.007. View

Murray M, Halsall D, Hook C, Williams D, Nicholson J, Coleman N . Identification of microRNAs From the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol. 2010; 135(1):119-25. DOI: 10.1309/AJCPOE11KEYZCJHT. View

Javadpour N . The role of biologic tumor markers in testicular cancer. Cancer. 1980; 45(7 Suppl):1755-61. View

10.

Badia R, Abe D, Wong D, Singla N, Savelyeva A, Chertack N . Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. J Urol. 2020; 205(1):137-144. DOI: 10.1097/JU.0000000000001337. View

11.

Dieckmann K, Dumlupinar C, Radtke A, Matthies C, Pichler R, Paffenholz P . Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. World J Urol. 2021; 40(2):317-326. PMC: 8921024. DOI: 10.1007/s00345-021-03876-2. View

12.

Belge G, Grobelny F, Radtke A, Bodes J, Matthies C, Wulfing C . Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. J Cancer Res Clin Oncol. 2020; 147(2):435-443. PMC: 7817581. DOI: 10.1007/s00432-020-03429-x. View

13.

Belge G, Dumlupinar C, Nestler T, Klemke M, Torzsok P, Trenti E . Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Clin Cancer Res. 2023; 30(2):404-412. PMC: 10792362. DOI: 10.1158/1078-0432.CCR-23-0730. View

14.

Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L . STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015; 351:h5527. PMC: 4623764. DOI: 10.1136/bmj.h5527. View

15.

Stephenson A, Eggener S, Bass E, Chelnick D, Daneshmand S, Feldman D . Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019; 202(2):272-281. DOI: 10.1097/JU.0000000000000318. View

16.

Lobo J, Leao R, Gillis A, van den Berg A, Anson-Cartwright L, Atenafu E . Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol. 2020; 4(3):483-491. DOI: 10.1016/j.euo.2020.11.004. View

17.

Morup N, Rajpert-De Meyts E, Juul A, Daugaard G, Almstrup K . Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up-A Copenhagen Experience. Cancers (Basel). 2020; 12(3). PMC: 7140092. DOI: 10.3390/cancers12030759. View

18.

Paffenholz P, Held L, Loosen S, Pfister D, Heidenreich A . Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches. J Urol. 2018; 200(2):353-360. DOI: 10.1016/j.juro.2018.03.007. View

19.

Dieckmann K, Isbarn H, Grobelny F, Dumlupinar C, Utschig J, Wulfing C . Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates-A Comprehensive Statistical Analysis. Cancers (Basel). 2022; 14(21). PMC: 9653836. DOI: 10.3390/cancers14215447. View

20.

Gilligan T, Seidenfeld J, Basch E, Einhorn L, Fancher T, Smith D . American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010; 28(20):3388-404. DOI: 10.1200/JCO.2009.26.4481. View